Social media

Only 16% of surveyed oncology researchers reported using AI in biomarker detection and assessment at the time of the survey, but nearly half (49%) identified it as the area where AI and ML could most accelerate oncology ...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Meet ICON experts at the AASLD to learn how ICON partners with sponsors, investigators, patients and other collaborators to deliver strategic, data-driven solutions for MASH and hepatology studies. https://ow.ly/TnAi50X8...

Meet ICON experts at the AASLD to learn how ICON partners with sponsors, investigators, patients and other collaborators to deliver strategic, data-driven solutions for MASH and hepatology studies. https://ow.ly/6a6M50X8...

Journals & Congresses offers rejection rate insights. You can review rejection rates by journal, helping target the best fit for your submission. Check out our interactive dashboard and see for yourself. https://ow.ly/ex...

Journals & Congresses offers rejection rate insights. You can review rejection rates by journal, helping target the best fit for your submission. Check out our interactive dashboard and see for yourself. https://ow.ly/Uw...

SLRs are more than academic exercises—they’re strategic tools that guide regulatory, clinical, and commercial decisions. ICON’s expert team delivers tailored, publication-ready reviews that meet your goals and timelines....

Recruitment in rare disease trials is never easy, especially with complex endpoints and direct competition. Discover how ICON helped a sponsor overcome these hurdles in two pivotal HCM trials through targeted site selec...

It is now common to pursue multiple indications for a single drug. But what is the most strategic approach to accelerating cross-indication approvals? Read the article for ICON's insights. https://ow.ly/a5po50XapWF

A 2025 ICON survey reflected the persistent use of conventional trial formats for emerging obesity drugs with multi-indication potential. However, nontraditional trial formats can be better suited to multi-indication dev...

ICON will be participating in ACOP 2025 in Aurora, Colorado, where we will introduce Yi Zhang, our new Scientific Director of PK in the Pharmacometrics Department. Yi brings extensive expertise in PK/PD modeling, disea...